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Background: This study compared palonosetron and ondansetron as rescue medications for postoperative nausea
and vomiting (PONV) in patients who received prophylactic ondansetron. Although guidelines recommend use of
an agent from a different class when prophylaxis has failed, palonosetron has unique properties relative to other
serotonin 5-HT3 receptor antagonists. Prior trials assessing its use for rescue have had conflicting results. Although
palonosetron has compared favorably with ondansetron for PONV prevention, the drugs have not been compared
in the rescue setting of failure of 5-HT3 receptor antagonist prophylaxis.
Methods: This was a randomized, open-label, multicenter trial comparing the efficacy and safety of intravenous
palonosetron 0.075 mg and intravenous ondansetron 4 mg in patients experiencing PONV following laparoscopic
abdominal or gynecological surgery despite prophylactic ondansetron.
Results: Of 239 patients screened, 220 were enrolled and 98 were treated for PONV: 48 and 50 in the palonosetron
and ondansetron arms, respectively. Complete control during 72 hours after study drug administration was
achieved in 25.0% of palonosetron recipients and 18.0% of ondansetron recipients (95% confidence interval
[CI], −9.2, 23.3; p = 0.40). Corresponding incidences of vomiting were 29.2% for palonosetron and 48.0% for
ondansetron (95% CI, −0.06, 37.7; p = 0.057), and 62.5% and 56.0% required additional rescue treatment, respectively
(95% CI, −25.9, 12.9; p = 0.52). Other than a similar incidence of procedural pain in the 2 groups, the most common
treatment-emergent adverse events, which were generally mild, were headache (14.6% vs 12.0%), constipation
(8.3% vs 10.0%), and dizziness (6.3% vs 8.0%), for the palonosetron and ondansetron groups, respectively.
Conclusions: Palonosetron and ondansetron did not show differences in the primary efficacy endpoint of CC
during the 72 hours after study drug administration. There was a trend toward less emesis in the 0–72 h time
period favoring palonosetron. While larger studies are needed to fully assess any clinical benefits of palonosetron to
rescue patients who have failed ondansetron prophylaxis for PONV, the benefit, if any, would be limited based on
this study.
Trial registration: ClinicalTrials.gov, NCT00967499 (Registered August 27, 2009)
Keywords: Postoperative nausea and vomiting, Antiemetics, Palonosetron, Ondansetron* Correspondence: KCandiot@med.miami.edu
1University of Miami–Jackson Memorial Hospital, 1611 NW 12th Avenue,
Room 300, 33136 Miami, FL, USA
Full list of author information is available at the end of the article
© 2014 Candiotti et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Candiotti et al. BMC Pharmacology and Toxicology 2014, 15:45 Page 2 of 8
http://www.biomedcentral.com/2050-6511/15/1/45Background
Postoperative nausea and vomiting (PONV) is a frequent
complication of surgery, with considerable medical and
economic impact, and is associated with high levels of
patient discomfort and dissatisfaction [1]. PONV is an
especially distressing adverse event to many patients,
often feared more than postoperative pain [1,2]. The
incidence of PONV is estimated at 25% to 30% in all
patients and as high as 80% in patients with multiple
high-risk factors [3,4].
PONV, alone or combined with pain, is one of the
leading causes for delayed discharge or unplanned hospital
admission following outpatient surgery [5-7]. PONV can
occur during the day after a surgical procedure or beyond
[8]. In the first 24 hours postoperatively, the highest inci-
dence of emetic sequelae is observed in patients undergo-
ing laparoscopic gynecologic surgery or receiving general
anesthesia [9,10]. Abdominal surgery is also a risk factor
for PONV, with an incidence in excess of 50% [1]. The
overall incidence of PONV after general anesthesia in
outpatients has been reported to be 37%, although sev-
eral factors, including sex, age, history of PONV, and
opiate administration, influence the risk [11].
The serotonin 5-HT3 receptor antagonists (RAs) com-
monly are used for prophylaxis of PONV; however, there
are fewer trials examining their use for treatment and
rescue of PONV. Guidelines from the Society for Ambula-
tory Anesthesia (SAMBA) recommend that when PONV
occurs after antiemetic prophylaxis, an agent from a differ-
ent class should be used as rescue treatment [12]. Candiotti
and colleagues investigated 88 women who developed
PONV after ondansetron prophylaxis; these patients were
randomly assigned to receive a repeat dose of ondansetron
4 mg, granisetron 1 mg, or granisetron 0.1 mg and were
then followed for 24 hours [13]. The authors concluded
that patients who failed ondansetron prophylaxis did not
have a significant response to crossover administration of
another 5-HT3 RA (ie, granisetron). In contrast, de Wit
et al. demonstrated a benefit to rescue administration using
granisetron and dexamethasone in patients receiving highly
emetogenic chemotherapy who had failed ondansetron
and dexamethasone prophylaxis [14]. Note that the
former study evaluated PONV, while the latter assessed
cancer-induced nausea and vomiting; differences may
exist between these 2 populations. Thus, this issue re-
mains unsettled.
Palonosetron is a pharmacologically distinct 5-HT3
RA with a greater binding affinity and longer half-life
than older agents in this class [15]. Binding isotherms,
equilibrium diagnostic tests, and kinetic diagnostic tests
show that palonosetron is an allosteric antagonist with
positive cooperativity, unlike ondansetron and granise-
tron. Differential effects on [3H]-ligand binding indicate
that palonosetron interacts at different or additionalsites on the 5-HT3 receptor compared with the binding
profiles of granisetron or ondansetron. Unlike these
agents, palonosetron also elicits 5-HT3 receptor intern-
alization and promotes extended inhibition of receptor
activity [16].
Two studies have shown that, compared with placebo,
a single intravenous dose of palonosetron 0.075 mg ef-
fectively reduced emesis, nausea intensity, and rescue
medication use in patients, particularly within 24 hours
after surgery [17,18]. When directly compared with
ondansetron before laparoscopic surgery or thyroidec-
tomy, palonosetron showed similar or superior efficacy
for prevention of PONV [19-23]; however, to our know-
ledge use of palonosetron as rescue therapy after ondanse-
tron failure has not been assessed. The pharmacological
profile of palonosetron, combined with its efficacy and fa-
vorable comparisons with ondansetron for the prevention
of PONV, prompted the hypothesis that palonosetron
may be effective as rescue therapy in patients for whom
preoperative prophylaxis with another 5-HT3 RA had
been unsuccessful, despite SAMBA recommendations
to use an agent from another class [12]. The current
phase II study evaluated the safety and efficacy of intra-
venous palonosetron 0.075 mg and intravenous ondan-
setron 4 mg (the currently approved doses) as rescue
medications in patients experiencing PONV in the post-
anesthesia care unit (PACU) following unsuccessful
prophylaxis with ondansetron.
Methods
This was a randomized, open-label, multicenter trial that
compared palonosetron with ondansetron using a 1:1
ratio as rescue therapy in outpatients who developed
PONV in the PACU after receiving prophylactic ondan-
setron. Study objectives were to assess efficacy and safety
of palonosetron and ondansetron when used in outpa-
tients as rescue therapy for PONV in the PACU. The
study was registered with ClinicalTrials.gov on August
27, 2009 (NCT00967499). Approval of the research proto-
col was required by each study center’s institutional review
board/ethics committee prior to patient randomization,
and the study complied with the Declaration of Helsinki
and Good Clinical Practice guidelines (the International
Conference on Harmonisation), with written informed
consent obtained from all patients. This was an open-label
study, and study drug preparation and dispensing were
performed by the site pharmacist. A list of study sites and
investigators is provided in Additional file 1.
Patient selection
Outpatients undergoing elective laparoscopic abdominal
or gynecological surgery who required general endo-
tracheal anesthesia for ≥30 minutes were eligible for
randomization if they met these criteria: ≥18 years of
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ical status I to III, and ≥2 of the following PONV risk
factors: female, nonsmoker, and history of PONV and/or
currently prone to motion sickness. Exclusion criteria in-
cluded chemotherapy within 4 weeks or emetogenic
radiotherapy within 8 weeks of study entry; body mass
index >40 kg/m2, use of investigational drugs within
30 days of study entry; use of drugs with potential anti-
emetic efficacy; or any nausea, vomiting, or retching
within 24 hours prior to anesthesia.
Treatment regimen and study design
On the day of surgery, patients received preoperative
intravenous ondansetron 4 mg before induction of
anesthesia per dosing and timing approved by the Food
and Drug Administration (FDA). All patients had intra-
venous induction of general anesthesia per the standard
of care at each site, were intubated, and received neuro-
muscular blockade, with reversal at the end of surgery
as indicated. Regional or total intravenous anesthesia
was not allowed. Using a minimization random alloca-
tion ratio, patients were randomized to rescue treat-
ment with either intravenous palonosetron 0.075 mg or
intravenous ondansetron 4 mg, both provided by Eisai Inc.
Patients with symptoms requiring a rescue antiemetic—
nausea score ≥4 on an 11-point Numeric Rating Scale
(NRS), retching or vomiting, or patient request—within
6 hours of PACU admission were given the randomized
drug within 10 minutes of investigator determination of
necessity. The NRS was an 11-point linear scale on which
patients rated their nausea, with 0 meaning no nausea and
10 meaning the worst possible nausea. These doses were
selected because they correspond with those approved by
the FDA for prevention of PONV and were anticipated to
provide maximal effect.
Patients were assessed for their overall response to the
rescue medication, and discharge from the PACU was
not affected by study participation. Baseline assessments
occurred at a screening visit within 2 weeks before the
surgery (day 1), and efficacy and safety were evaluated at
0.5, 1, 2, 6, 12, 24, 48, and 72 hours after dosing with the
rescue medication. After discharge from the PACU, all
patients received a follow-up telephone call to review
the patient diary, in which they were instructed to rec-
ord emetic episodes, nausea severity (subjectively rated
by patient) and duration, use of additional rescue drugs,
and functioning related to nausea/emesis. In addition to
baseline, the NRS was completed at the previously men-
tioned evaluation time points, with patients asked to rate
the most severe nausea they had experienced since the
last assessment.
The primary efficacy endpoint was the proportion of
patients who achieved complete control (CC), defined as
no emetic episode, no rescue medication, and a nauseaseverity score of ≤3 on the NRS, from 0 to 72 hours after
rescue dosing. The percentage of patients with CC 0 to
30, 30 to 60, and 60 to 120 minutes also was assessed.
Secondary efficacy endpoints were complete response
(CR), defined as no emetic episode and no rescue medi-
cation; the proportions of patients with no emesis and
no additional rescue medication in the 72 hours follow-
ing the rescue dose; and the change from baseline nau-
sea score using the NRS. Treatment-emergent adverse
events (TEAEs), regardless of suspected causal relation-
ship to the study medication, were recorded throughout.
Statistical considerations
It was estimated that approximately 300 patients would
need to be randomized to have 100 patients treated with
either palonosetron or ondansetron; as this study was
for proof of concept, no statistical justification of sample
size was done. Patients were assigned to a treatment
group using a minimization random allocation ratio. The
primary efficacy parameter was analyzed using the full
analysis set population, consisting of all patients who were
randomized to and received study drug. Safety was evalu-
ated for all randomized patients given rescue medication
and who had ≥1 safety assessment after treatment.
Descriptive statistics were used for most primary and
secondary efficacy parameters, as well as safety data. The
Cochran-Mantel-Haenszel test was used to compare the
CC rates between treatment groups, stratified to sex at a
2-sided significance level of 0.05. All secondary end-
points were analyzed using the same methods.
Results
Study disposition and baseline characteristics
Patients were recruited from July 2009 to December
2009. Of 239 patients screened, 220 patients were ran-
domized from 10 centers. See Figure 1 for complete pa-
tient disposition. In all, 98 patients experienced PONV
that required rescue medication within 6 hours of PACU
admission and were included in the study assessment.
The patient demographics and baseline characteristics
were similar in the palonosetron and ondansetron groups
(Table 1). All patients were female, and most were non-
smokers. Most patients had low ASA scores (I or II).
Complete control
As shown in Table 2, CC through 72 hours after dosing
was achieved by 25.0% of palonosetron patients compared
with 18.0% of ondansetron patients (95% confidence inter-
val [CI], −9.2, 23.3; p = 0.40). Assessment of the initial
24 hours demonstrated a similar efficacy profile, while
efficacy increased for both drugs during the 24- to 72-
hour time period, with CC reached by a similar portion
of patients in both groups.
Sponsor decision (n = 1) 
Allocated to palonosetron (n = 111) 
Treated (n = 48)
Not treated (no PONV within 6 h) (n = 63) 
Excluded (n = 19)
Other reasons (n = 4)
Assessed for eligibility (n = 239) 
Randomized (n = 220)
Analyzed (n = 50) 
Adverse event (n = 1)
Allocated to ondansetron (n = 109) 
Treated (n = 50) 
Not treated (no PONV within 6 h) (n = 59)




Figure 1 CONSORT flow diagram of patient disposition.
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ondansetron patients achieved CC within the first 30 mi-
nutes of dosing. Across the 3 time periods examined
during the first 120 minutes, CC ranged from 50.0% to
66.7% in the palonosetron group and from 58.0% to
62.0% in the ondansetron group.
Secondary efficacy endpoints
The secondary endpoints of CR, no emesis, and no add-
itional rescue medication are shown in Table 3 for the 0-
to 72-, 0- to 24-, and 24- to 72-hour time periods. With
the exception of a result that possibly favored palonose-
tron over ondansetron for no emesis over the entire 72-
hour evaluation period (p = 0.057), none of the other
comparisons approached statistical significance.
Prior to rescue medication administration, moderate
nausea (as rated subjectively by patient) was experienced
by 66.7% of patients in the palonosetron group and
62.0% of patients in the ondansetron group. After 24 hours
no nausea was reported by 83.3% and 82.0% of patients
treated with palonosetron and ondansetron, respectively,
and at the end of 72 hours no nausea was recorded
by 79.2% and 82.0% of palonosetron and ondansetronpatients, respectively. Baseline NRS severity scores were
similar for the 2 groups (5.7 and 5.9 in the palonosetron
and ondansetron arms, respectively). Changes were
most substantial in the 24- to 72-hour time period,
with similar decreases in NRS scores, ranging from −5.1
to −5.3 and −5.3 to −5.6 in the palonosetron and ondanse-
tron arms, respectively.
Safety profile
The safety profiles for palonosetron and ondansetron
were comparable, with a similar number of patients ex-
periencing TEAEs during the 72-hour evaluation period
(Table 4). Other than procedural pain, which was not
substantially different between groups, the most com-
mon TEAEs in both groups were headache, constipation,
and dizziness: 14.6%, 8.3%, and 6.3% and 12.0%, 10.0%,
and 8.0% in the palonosetron and ondansetron groups,
respectively. Most TEAEs were mild, but 6 palonosetron
patients (12.5%) and 8 ondansetron patients (16.0%) expe-
rienced serious TEAEs, primarily gastrointestinal effects.
No serious TEAEs were attributed to treatment with palo-
nosetron, and 1 (2.0%) serious TEAE was thought to be
related to ondansetron treatment.
Table 1 Baseline patient demographics and clinical characteristics
Palonosetron Ondansetron Total
(n = 48) (n = 50) (N = 98)
Age (y)
Mean (SD) 41 (10.2) 43 (13.8) 42 (12.1)
Min, max 22, 62 21, 83 21, 83
Sex
Female, n (%) 48 (100.0) 50 (100.0) 98 (100.0)
Race, n (%)
White 36 (75.0) 36 (72.0) 72 (73.5)
Black or African American 7 (14.6) 9 (18.0) 16 (16.3)
Asian 1 (2.1) 3 (6.0) 4 (4.1)
Other 4 (8.3) 2 (4.0) 6 (6.1)
Nonsmoker*, n (%) 45 (93.8) 49 (98.0) 94 (95.9)
BMI (kg/m2)
Mean (SD) 27.2 (5.4) 27.8 (5.0) 27.5 (5.2)
Min, max 17, 38 20, 39 17, 39
Duration of laparoscopic surgery (min)
Mean (SD) 113.3 (69.4) 102.0 (59.8) 107.6 (64.6)
Median 92.5 81.5 88.5
Min, max 26, 306 34, 282 26, 306
Baseline NRS for nausea severity
n 47 48 95
Mean (SD) 5.7 (1.84) 5.9 (1.86) 5.8 (1.84)
Min, max 2, 10 3, 10 2, 10
History of PONV†, n (%) 30 (62.5) 27 (54.0) 57 (58.2)
Type of laparoscopic surgery, n (%)
Gynecological 37 (77.1) 31 (62.0) 68 (69.4)
Abdominal 11 (22.9) 19 (38.0) 30 (30.6)
ASA classification, n (%)
I 20 (41.7) 20 (40.0) 40 (40.8)
II 25 (52.1) 24 (48.0) 49 (50.0)
III 3 (6.3) 6 (12.0) 9 (9.2)
Baseline opioid use, n (%) 47 (97.9) 50 (100.0) 97 (99.0)
Abbreviations: ASA American Society of Anesthesiologists, BMI body mass index, NRS Numeric Rating Scale, PONV postoperative nausea and vomiting,
SD standard deviation.
*Never smoked or quit ≥12 months before participation in the study. †History of PONV and/or currently prone to motion sickness.
Table 2 Complete control achieved—primary efficacy endpoint
Palonosetron (n = 48) Ondansetron (n = 50) Difference, % p-value
n (%) n (%) (95% CI)
0-72 h 12 (25.0) 9 (18.0) 7.0 (−9.2, 23.2) 0.40
0-24 h 12 (25.0) 10 (20.0) 5.0 (−11.5, 21.5) 0.56
24-72 h 40 (83.3) 40 (80.0) 3.3 (−12.0, 18.6) 0.67
Abbreviation: CI confidence interval.
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(95% CI)n (%) n (%)
Complete response
0-72 h 15 (31.3) 13 (26.0) 5.3 (−12.6, 23.1) 0.57
0-24 h 15 (31.3) 15 (30.0) 1.3 (−17.0, 19.5) 0.89
24-72 h 43 (89.6) 41 (82.0) 7.6 (−6.1, 21.3) 0.29
No emesis
0-72 h 34 (70.8) 26 (52.0) 18.8 (−0.06, 37.7) 0.057
0-24 h 34 (70.8) 29 (58.0) 12.8 (−5.9, 31.6) 0.19
24-72 h 45 (93.8) 44 (88.0) 5.8 (−5.6, 17.1) 0.33
No additional rescue medication
0-72 h 18 (37.5) 22 (44.0) −6.5 (−25.9, 12.9) 0.52
0-24 h 18 (37.5) 23 (46.0) −8.5 (−28.0, 11.0) 0.40
24-72 h 44 (91.7) 43 (86.0) 5.7 (−6.7, 18.1) 0.38
Abbreviation: CI confidence interval.
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The use of prophylactic antiemetics is intended to pre-
vent episodes of vomiting, eliminate or lessen the sever-
ity of nausea, and minimize or remove the need for
PONV rescue medications. 5-HT3 RAs have proven ef-
fective for the prevention and treatment of PONV, with
minimal adverse effects [12]. As a class, 5-HT3 RAs are
generally safe at the usual doses used to prevent or treat
PONV, with no dose-related sedation or extrapyramidal
reactions and no significant effects on vital signs [24].
For prophylaxis of PONV, palonosetron has demon-
strated efficacy similar to or superior to ondansetron
[19-23]; however, they have not been compared for res-
cue after ondansetron failure. If patients who receive no
antiemetic prophylaxis before surgery experience PONV,
a 5-HT3 RA may be of benefit [12]. According to the
SAMBA guidelines, if patients experience PONV after
prophylaxis was given, an agent should be chosen from
a therapeutic class different from the one administered
prophylactically [12]. Because the mechanism of action
and pharmacokinetics for palonosetron differ substantiallyTable 4 Treatment-emergent adverse events
Palonosetron Ondansetron Total
(n = 48) (n = 50) (N = 98)
TEAEs 43 (89.6) 49 (98.0) 92 (93.9)
Treatment-related AEs 5 (10.4) 4 (8.0) 9 (9.2)
Serious TEAEs 6 (12.5) 8 (16.0) 14 (14.3)
Treatment-related
serious TEAEs
0 (0.0) 1 (2.0) 1 (1.0)
Deaths 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviations: AEs adverse events, TEAEs treatment-emergent adverse events.
All data reported as n (%).from other 5-HT3 RAs, its use seemed reasonable when
ondansetron had failed. Ondansetron rescue of ondanse-
tron prophylaxis served as an active drug comparator with
previously known results.
The primary endpoint of the study, proportion of pa-
tients achieving CC over the 72-hour evaluation period,
was achieved in 25.0% and 18.0% of patients receiving
PONV rescue treatment with palonosetron and ondan-
setron, respectively, showing no statistical difference
(p = 0.40). The lack of statistical significance affirms an
earlier study assessing granisetron rescue therapy fol-
lowing failed ondansetron prophylaxis [13]. Contrary
to our estimate that 100 patients per treatment group
would be appropriate, a post hoc power analysis showed
that approximately 540 patients actually would be needed
per arm to demonstrate a statistically significant difference
in the primary endpoint with the results seen here (25.0%
vs 18.0%). However, at the time, the study was carried out
assuming a much larger treatment difference between
palonosetron and ondansetron arms.
The 95% CI for the difference ranged from −9.2% (fa-
voring ondansetron) to 23.2% (favoring palonosetron).
Because the pharmacology of palonosetron differs from
other 5-HT3 RAs, as described earlier, it seemed plaus-
ible that palonosetron might prove effective when an-
other agent from the same class already has been used
for PONV prophylaxis. If there is a difference, however,
it would seem to be small based on this study. Differences
in the 0- to 24-hour and 24- to 72-hour time periods also
were not statistically significant.
Among the secondary outcomes of CR, no emesis, and
no additional rescue medication, differences between the
two arms showed a lack of statistical significance at all
times. However, as with the primary endpoint, the 95%
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differences between palonosetron and ondansetron can-
not be ruled out. Over the entire 72-hour assessment
period, a lack of emesis was reported by 70.8% and
52.0% (95% CI −0.06, 37.7; p = 0.057) of palonosetron
and ondansetron patients, respectively, showing a trend
toward statistical significance, possibly due to the much
longer half-life of palonosetron. Patient self-reported
nausea showed similar improvements with palonosetron
and ondansetron. The safety analyses demonstrated that
both palonosetron and ondansetron were well tolerated,
with no notable differences in safety parameters between
groups.
Limitations of the current study include the lack of blin-
ding, the timing of ondansetron prophylaxis, and the dosing
of drugs. Drug dosing and time of administration needed to
be consistent with FDA-approved labeling, so alternative
methods of administration recommended by others could
not be evaluated here. The most recent SAMBA guidelines
recommend giving prophylactic ondansetron at the end of
surgery, while administering palonosetron prior to surgery
[12]. In this study, ondansetron was given at the induction
of anesthesia, as per product labeling; however, this is not
likely to have influenced rescue therapy. In addition,
SAMBA guidelines recommend use of a different class of
agent from the one given for PONV prophylaxis for PONV
rescue; however, palonosetron was evaluated in this trial be-
cause of its unique pharmacological properties compared
with other 5-HT3 RAs, as described earlier. The authors
acknowledge that we could potentially learn more from a
study designed with a different comparator than ondan-
setron (eg, an antiemetic with a different mechanism of ac-
tion relative to the 5-HT3 RAs). In addition, although the
study was open to both males and females, male patients
were unable to be recruited. The incidence of PONV is
higher in females, but the results cannot necessarily be ex-
trapolated to males.Conclusions
Palonosetron and ondansetron did not show differences in
the primary efficacy endpoint of CC during the 72 hours
after study drug administration. At the earliest time points,
there were no differences between palonosetron and
ondansetron treatment, but in the full 0- to 72-hour period,
there was a trend toward greater efficacy for palonosetron
for patients experiencing no emesis after rescue, possibly
because the longer half-life of palonosetron may make it
more effective than ondansetron for delayed emesis. Out-
side of this trend toward less emesis overall, there does not
appear to be a significant difference between palonosetron
and ondansetron for rescue treatment of PONV after fail-
ure of ondansetron prophylaxis, supporting the SAMBA
recommendations to use an antiemetic from another class.Additional file
Additional file 1: Study site investigators.
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